Cutaneous Polyionic Therapeutics

Information

  • Research Project
  • 7927206
  • ApplicationId
    7927206
  • Core Project Number
    R43AR059565
  • Full Project Number
    1R43AR059565-01
  • Serial Number
    59565
  • FOA Number
    RFA-OD-09-009
  • Sub Project Id
  • Project Start Date
    4/1/2010 - 14 years ago
  • Project End Date
    9/30/2010 - 13 years ago
  • Program Officer Name
    CIBOTTI, RICARDO
  • Budget Start Date
    4/1/2010 - 14 years ago
  • Budget End Date
    9/30/2010 - 13 years ago
  • Fiscal Year
    2010
  • Support Year
    1
  • Suffix
  • Award Notice Date
    3/26/2010 - 14 years ago
Organizations

Cutaneous Polyionic Therapeutics

DESCRIPTION (provided by applicant): Many human skin diseases display a hyperproliferative or proliferative epidermis, or cutaneous inflammation, or combinations of these two pathological characteristics. As an example, the keratinocytes of the psoriatic epidermis are both hyperproliferative and produce elevated levels of the Amphiregulin EGF-like growth factor, and the IL-8, ILalpha and TNF-alpha cytokines, which could both attract and activate inflammatory cells, and promote psoriatic epidermal keratinocyte hyperproliferation. Additionally, the aberrant activity of the immune system may direct the mitogenic activation of these cells by activating the endogenous epidermal growth factor (EGF) pathway in the psoriatic epidermal keratinocytes. Our proposed investigation will examine activity of charged polymeric compounds that may block the EGF pathway in human keratinocyte cultures and penetrate into reconstructed human epidermis the results of the proposed study will determine whether these charged compounds might represent new non-steroidal drugs for further testing as therapeutics for inflammatory-proliferative human skin disease such as psoriasis and dermatitis. PUBLIC HEALTH RELEVANCE: This proposal is designed to synthesize and test new drugs for the treatment of the commonly observed human inflammatory-proliferative skin diseases such as psoriasis and dermatitis. It is hoped that the results of this study will produce new, safe and effective topical therapies for individuals suffering from these common skin diseases.

IC Name
NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES
  • Activity
    R43
  • Administering IC
    AR
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    100000
  • Sub Project Total Cost
  • ARRA Funded
    True
  • CFDA Code
    701
  • Ed Inst. Type
  • Funding ICs
    OD:100000\
  • Funding Mechanism
    SBIR-STTR
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    AVANTBIO CORPORATION
  • Organization Department
  • Organization DUNS
    015954587
  • Organization City
    VANCOUVER
  • Organization State
    WA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    986650013
  • Organization District
    UNITED STATES